Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

The Journal of Heart and Lung Transplantation（2022）

引用 9|浏览18

暂无评分

摘要

While sole improvements in 6MWD and NT-proBNP had minor prognostic relevance, improvements in multicomponent endpoints and risk stratification tools based on FC, 6MWD, and NT-proBNP were associated with improved survival. These tools should be further explored as outcome measures in PAH trials.

查看译文

关键词

pulmonary arterial hypertension,treatment,clinical trials,endpoints,risk,mortality

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要